


RC  
267  
N26  
1983  
pt.5



Gift (1-15-87)







*National Cancer Institute (U.S.)  
Annual report.*

Division of

---

# RESOURCES, CENTERS & COMMUNITY ACTIVITIES

---

1983 Annual Report  
October 1, 1982-September 30, 1983

U.S. DEPARTMENT  
OF HEALTH  
AND HUMAN SERVICES

National  
Institutes of  
Health

National  
Cancer  
Institute



National Cancer Institute

RC  
267  
N26  
1983  
pt. 5



LISTING OF 6040 FORMS  
INTRAMURAL RESEARCH PROJECTS

Z01 CN 00100 CPSB - U.S.-Finland Epidemiologic Studies of Nutrition and Cancer

Z01 CN 00101 CPSB - Human Studies of Diet and Nutrition

Z01 CN 00102 CPSB - Phase I Studies of Synthetic Retinoids

Z01 CN 00103 CPSB - Use of Isotretinoin in Prevention of Basal Cell Carcinoma

Z01 CN 00104 CPSB - NHANES I Epidemiologic Follow-up Survey:  
Chemoprevention/Nutrition Aspects

Z01 CN 00105 BORB - Research in Cancer Screening Methodology and Modeling

Z01 CN 00106 BORB - Students Cancer Screening

Z01 CN 00107 BORB - Incidence of Basal Cell Skin Carcinoma in a  
High Risk Population

Z01 CN 00108 BORB - Design of Pharmacokinetic Studies of Selenium

Z01 CN 00109 BORB - Development of Cancer Control Epidemiology and Tracking

Z01 CN 00110 BORB - Data Management and Design in Clinical Trials for  
Cancer Prevention and Control

Z01 CN 00111 BORB - Core Data and Dietary Methodology

Z01 CN 00112 BORB - Retrospective Dietary Assessment



# Appendix B

INTRAMURAL PROJECT SUMMARIES (Forms PHS 6040)

九  
 十  
 十一  
 十二  
 十三  
 十四  
 十五  
 十六  
 十七  
 十八  
 十九  
 二十  
 二十一  
 二十二  
 二十三  
 二十四  
 二十五  
 二十六  
 二十七  
 二十八  
 二十九  
 三十

DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE NOTICE OF INTRAMURAL RESEARCH PROJECT		PROJECT NUMBER Z01 CN 00100 CPSB
PERIOD COVERED October 1, 1982 - September 30, 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) U.S.-Finland Epidemiologic Studies of Nutrition and Cancer		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute of affiliation) Demetrius Albanes, M.D., Medical Officer		
COOPERATING UNITS (If any)		
LAB/BRANCH Cancer Prevention Studies Branch, DRCCA		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 1.4	PROFESSIONAL: 1.20	OTHER: 0.20
CHECK APPROPRIATE BOX(ES) <input checked="" type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unrounded type. Do not exceed the space provided.)  <p>The important relationship of diet and nutrition in the development of cancer has become well known through various research efforts. Laboratory studies have shown cancer inhibitory functions for various natural and synthetic nutrients in various models, which have been corroborated by human epidemiologic studies of of nutrient intake, tissue levels and cancer incidence. Vitamin A, beta-carotene and selenium have been strongly implicated for their cancer preventive potential, with evidence for the former two substances warranting clinical trials of their efficacy. In addition, the roles of other nutrients in cancer cause and prevention (e.g., dietary fats and fiber) require further investigation.</p> <p>The objectives of the project are: 1) to determine if beta-carotene supplementation is effective in preventing lung cancer in smokers; 2) to better assess the role of selenium, vitamins A, E, and C, and fats in breast cancer development; 3) to investigate the role of various nutrients (in prenatal maternal blood) for the development of cancer in children, and 4) to evaluate the roles of various levels of nutrient intake to subsequent cancer.</p> <p>The project includes four studies all of which take place in Finland. The first, a beta-carotene, lung cancer intervention trial, is a five-year, double-blind, placebo-controlled, randomized trial of daily beta-carotene supplementation (15 mg. orally) among cigarette smokers. Any reduction of lung cancer incidence in the beta-carotene group will be measured. The second is a breast cancer case-control study of selenium, vitamins A, E, C, fats and other nutrients (both serum levels and dietary history), using both benign breast disease and neighborhood controls. The importance of these nutrients in breast cancer development will be assessed. The dietary survey study will use previously collected dietary history information for a subgroup having developed cancer out of our original population cohort. Associations between various dietary components and different cancers will be assessed. The fourth study is a case-control investigation of prenatal maternal nutritional status (i.e., nutrient blood levels) and subsequent early childhood cancer incidence in those offspring.</p>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE <b>NOTICE OF INTRAMURAL RESEARCH PROJECT</b>		PROJECT NUMBER Z01 CN 00101 CPSB
PERIOD COVERED October 1, 1982 - September 30, 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Human Studies of Diet and Nutrition		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) Kathy J. Helzlsouer, M.D., Medical Officer		
COOPERATING UNITS (if any)		
LAB/BRANCH Cancer Prevention Studies Branch, DRCCA		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 1.25	PROFESSIONAL: 1	OTHER: .25
CHECK APPROPRIATE BOX(ES) <input checked="" type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>The role of specific dietary factors in cancer prevention has been assessed through epidemiologic studies and animal experiments. For many of these agents, information is incomplete concerning their quality and form in the food supply, bioavailability, biochemical effects and the interaction with other nutrients. To further define these parameters in the human population, a cooperative research effort between the Beltsville Human Nutrition Research Center (BHNRC) and the Cancer Prevention Studies Branch, DRCCA, will be conducted. The three-year inter-agency agreement will encompass the development of analytical methods for routine analysis of nutrients as well as further investigation of the pharmacodynamics and interactions of those dietary factors identified as possible cancer preventive agents.</p> <p>The overall goal is to obtain further information on those factors identified as potential cancer preventive agents with respect to their quantity and bioavailability in the food supply, health effects of supplementation and their pharmacokinetics in a healthy population, as well as improving methods for analysis of these nutrients. Investigations of the trace element selenium (Se) will be done during the first year. To date, few supplemental studies have been done and many questions concerning the pharmacokinetics and bioavailability of Se in its organic and inorganic forms remain unanswered. In addition, most of these studies have been done in populations with low Se status and, therefore, results cannot be extrapolated to the U.S. population which appears to have adequate Se status. The initial phase of the Se studies will examine the pharmacokinetics of a single oral dose of selenite and selenomethionine in a healthy population who have adequate Se intake at baseline. The second phase will examine the bioavailability and health effects of multiple doses of inorganic and organic selenium. Following these, a study will be done correlating dietary intake of B-carotene with B-carotene levels, retinol and retinol-binding protein levels in the blood. Further studies will examine interactions of dietary fat and fiber intake on vitamin and mineral balance.</p>		





DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE NOTICE OF INTRAMURAL RESEARCH PROJECT		PROJECT NUMBER Z01 CN 00102 CPSB
PERIOD COVERED October 1, 1982 - September 30, 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Phase I Studies of Synthetic Retinoids		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) Earl C. Gross, M.D., and Joseph A. Tangrea, M.P.H., Senior Investigators		
COOPERATING UNITS (If any)  Dermatology Branch		
LAB/BRANCH Cancer Prevention Studies Branch, DRCCA		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 1.4	PROFESSIONAL: 1.2	OTHER: 0.2
CHECK APPROPRIATE BOX(ES) <input checked="" type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>The objective of the Phase I studies is to provide the parameters and characteristics of drug toxicity, the maximally tolerated dose, the recommended dose and the basic pharmacokinetics of these agents. Drugs tested will be limited to oral synthetic retinoids.</p> <p>Vitamin A and its synthetic analogs, collectively known as retinoids, have been actively studied in relation to their requirements in normal physiology and health as well as for their potential in prevention of human disease, notably cancer. In this regard, it has been established that: 1) Supplementation with retinoids can reverse tissue metaplasia and neoplasia in various laboratory models, restoring normal cell differentiation; and 2) Retinoids administered to animals can prevent chemical and viral induced carcinogenesis. They have been repeatedly shown to delay the appearance, retard the growth, cause the regression and prevent metastases of selected tumors. In addition, several epidemiological studies have shown an association of low levels of vitamin A with increased risk of cancer.</p> <p>Based on this evidence and case reports demonstrating the successful chemoprevention of basal cell carcinoma with large doses of the retinoid isotretinoin, Phase I clinical trials using other new oral synthetic retinoids are proposed. Three new oral synthetic retinoids will be evaluated over the next one-year period with therapeutic intent for the dermatologic conditions of acne, psoriasis, disorders of keratinization (ichthyoses and Darier's Disease), basal cell carcinoma and other related dermatologic disorders. The studies will be designed to allow dosage escalation from a presumed non-toxic dose to a dose showing either substantive efficacy or toxicity. When moderate toxicity is reached, modification to lower doses will be made and patients examined monthly for chronic toxicity. Maximum duration of continuous treatment will be six months.</p> <p>The specific objective is to establish safe and tolerated doses for conducting Phase II-III chemoprevention trials.</p>		

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846

## NOTICE OF INTRAMURAL RESEARCH PROJECT

Z01 CN 00103 CPSB

## PERIOD COVERED

October 1, 1982 - September 30, 1983

## TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.)

Use of Isotretinoin in Prevention of Basal Cell Carcinoma

## PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.)

(Name, title, laboratory, and institute affiliation)

Joseph A. Tangrea, M.P.H., Pharmaceutical Research Coordinator

## COOPERATING UNITS (If any)

Biometrics and Operations Research Branch, DRCCA

## LAB/BRANCH

Cancer Prevention Studies Branch, DRCCA

## SECTION

## INSTITUTE AND LOCATION

National Cancer Institute, NIH, Bethesda, MD

## TOTAL MANYEARS:

2.5

## PROFESSIONAL:

2.0

## OTHER:

0.5

## CHECK APPROPRIATE BOX(ES)

- ☒ (a) Human subjects      ☐ (b) Human tissues      ☐ (c) Neither  
☐ (a1) Minors  
☐ (a2) Interviews

## SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)

The study is a five-year randomized double-blind clinical trial designed to evaluate the effectiveness of low-dosage levels of isotretinoin in reducing the incidence of basal cell carcinomas in a high-risk population, and to examine possible side effects associated with long-term administration of low doses of isotretinoin. Approximately 1,800 evaluable subjects will be entered into the study within 12-18 months at ten participating clinical centers located around the country (military and Veterans Administration hospitals). At each center, subjects will be stratified and randomly allocated to intervention (10 mg/day) or control (placebo) groups.

Vitamin A and its analogs, collectively known as retinoids, have been actively studied for several years in relation to their requirements in normal physiology and health, as well as for their potential in prevention of human disease. This vitamin is necessary for the differentiation of epithelial cells and is essential for the development and function of growth, reproduction, and vision. Deprivation or deficiency of vitamin A promotes tissue metaplasia and neoplasia in various animal and organ culture models. Supplementation with retinoids can reverse these changes and restore functions of cell growth and differentiation in various cell lines.

Laboratory experiments have shown that retinoids administered to animals can prevent chemical carcinogenesis. Since in most of the experiments animals were administered retinoids after their exposure to the carcinogen, the prophylactic effect of the retinoids is believed to be in the post-initiation phase, i.e., during promotion of carcinogenesis. In addition, several epidemiological studies have shown an association of low dietary intake or serum levels of vitamin A with increased risk of cancer, notably lung cancer and other tumors of epithelial origin. Recent case reports have shown that isotretinoin can prevent the appearance of new basal cell carcinomas for four years in patients at high risk of developing new tumors.



DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE <b>NOTICE OF INTRAMURAL RESEARCH PROJECT</b>		PROJECT NUMBER Z01 CN 00104 CPSB
PERIOD COVERED October 1, 1982 - September 30, 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) NHANES I Epidemiologic Follow-up Survey: Chemoprevention/Nutrition Aspects		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) Gladys Block, Ph.D.		
COOPERATING UNITS (if any)  National Center for Health Statistics, DRCCA		
LAB/BRANCH Biometrics and Operations Research Branch		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 0.3	PROFESSIONAL: 0.2	OTHER: 0.1
CHECK APPROPRIATE BOX(ES) <input type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input checked="" type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>The purpose of the NHANES (National Health and Nutrition Examination Survey) Epidemiologic Follow-up Survey is to conduct a longitudinal study of 14,407 adults originally surveyed in 1971-1975, to investigate subsequent health and mortality outcome. Respondents will be traced and re-examined. Information will also be obtained from hospital records, the National Death Index and death certificates. The NHANES Follow-up Survey is well under way in the field.</p> <p>The purpose of this intramural project is to examine the relationship of chemopreventive and nutritional factors and cancer in the very large representative population which NHANES offers. It provides an opportunity to examine these factors and potentially confounding or modifying factors in a prospective fashion, and to examine the effectiveness or toxicity of some dietary agents which are currently of great interest for cancer prevention.</p> <p>The relationship of baseline vitamin use, biochemical or nutritional measures and subsequent health status will be examined. In addition, descriptive data and trends in potential risk factors or protective factors over time will be examined.</p> <p>The project will involve the recoding of certain baseline data, and the specification of an analysis plan to examine the relationships and trends described above. The National Center for Health Statistics will conduct preliminary analyses, and will participate with DRCCA in the development of more advanced analyses of these data.</p>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE NOTICE OF INTRAMURAL RESEARCH PROJECT		PROJECT NUMBER Z01 CN 00105 BORB
PERIOD COVERED October 1982 - September 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Research in Cancer Screening Methodology and Modeling		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) Philip C. Prorok, Ph.D.		
COOPERATING UNITS (If any) Biometry Branch, DCCP		
LAB/BRANCH Biometrics and Operations Research Branch, DRCCA		
SECTION Screening Section		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 0.4	PROFESSIONAL: 0.35	OTHER: 0.05
CHECK APPROPRIATE BOX(ES) <input type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>The focus of this project is development and refinement of statistical procedures for the design and analysis of screening, detection, and related studies in cancer. Statistical problems under investigation include sample size determination, comparison of analysis methods, and development of monitoring techniques and stopping rules. Each of these problem areas is common to screening and prevention trials in which the Division participates, but the methods for screening studies must address the special lead time and length biases inherent in screening programs.</p> <p>The research includes investigation of techniques to estimate and adjust for screening biases in the analysis of survival data, and the study of the relationship between long-term mortality and short-term outcome measures, such as stage shift. Probabilistic models of disease and screening are being developed to aid in the interpretation and evaluation of data from screening programs, and a breast cancer model relating doubling time to survival is under derivation in collaboration with the Biometry Branch, DCCP.</p>		





DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE NOTICE OF INTRAMURAL RESEARCH PROJECT		PROJECT NUMBER 201 CN 00106 BORB
PERIOD COVERED October 1982 - September 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Students Cancer Screening		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) Philip C. Prorok, Ph.D.		
COOPERATING UNITS (if any)		
LAB/BRANCH Biometrics Operations Research Branch, DRCCA		
SECTION Screening Section		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 0.4	PROFESSIONAL: 0.35	OTHER: 0.05
CHECK APPROPRIATE BOX(ES) <input checked="" type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input checked="" type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.) <p>           Data from several cancer screening studies are being analyzed to gain a better understanding of the impact and consequences of such screening in various population settings. The results can be used by NCI in establishing cancer control policy. These databases also provide the opportunity for the testing and development of new techniques for data analysis. Results from the Health Insurance Plan of New York (HIP) breast cancer screening trial continue to indicate a long-term reduction in breast cancer mortality. In collaboration with the Field Studies and Statistics Program of the Division of Cancer Cause and Prevention (FSS), long-term case survival patterns and co-variables are being related to population mortality measures to determine when and in which subsets of cases the screening benefit occurred. Patterns of cause of death among breast cancer cases are being studied to distinguish between postponement of death and cure.         </p> <p>           A group collaborating through the International Agency for Research on Cancer (IARC) is analyzing the cervical cancer screening programs in Scandinavia and Aberdeen, Scotland. The objective is to estimate false negative rates and natural history characteristics and relate these to the varying screening frequencies and delivery mechanisms in the participating countries. Two occupational high risk groups are under scrutiny. With FSS people, the bladder cancer screening program at the DuPont Company is being analyzed to relate disease characteristics and outcome to cytology and blood tests, smoking history and exposure to benzidine and <math>\beta</math>-naphthylamine. With FSS and the National Institute of Occupational Safety and Health (NIOSH), updated followup data are being collected in a study of sputum cytology screening for lung cancer among uranium miners. The relationships among cytology classification, radiation exposure, smoking history, lung cancer, and mortality data will be analyzed. Participation has begun in an International Union Against Cancer (UICC) screening evaluation project which will review screening data from worldwide sources and develop guidelines for UICC members.         </p>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE NOTICE OF INTRAMURAL RESEARCH PROJECT		PROJECT NUMBER  Z01 CN 00107 BORB
PERIOD COVERED <u>April 1983 - September 1983</u>		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) <u>Incidence of Basal Cell Skin Carcinoma in a High Risk Population</u>		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) <u>Anne Hartman, M.S. and Jancie Brown McPhillips</u>		
COOPERATING UNITS (If any)  <u>Cancer Prevention Studies Branch, Prevention Program, DRCCA</u>		
LAB/BRANCH <u>Biometrics and Operations Research Branch, DRCCA</u>		
SECTION  		
INSTITUTE AND LOCATION <u>National Cancer Institute, NIH, Bethesda, MD</u>		
TOTAL MANYEARS: <u>.6</u>	PROFESSIONAL: <u>0.5</u>	OTHER: <u>0.1</u>
CHECK APPROPRIATE BOX(ES) <input type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input checked="" type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>           This study is developing estimates for the incidence of new basal cell skin carcinoma. The importance of this study is twofold: to obtain incidence for basal cell skin carcinoma in a high risk population already exhibiting previous basal cell carcinoma lesions; and to support the basal cell skin carcinoma prevention trial launched in collaboration with the Prevention Program. (The Prevention Program is embarking on a five-year randomized double-blind clinical trial designed to evaluate the effectiveness of low dosage levels of isotretinoin in reducing the incidence of basal cell skin carcinomas in a high risk population. [Z01 CN 00102 CPSB]). The estimated number of new cancer cases, excluding non-melanoma skin cancer and carcinomas in situ for 1983, is 855,000. The incidence of non-melanoma skin cancer is estimated to be approximately 400,000, of which approximately 80%, or roughly 320,000 would be basal cell carcinoma. Although basal cell carcinoma is rarely fatal, these numbers represent a big impact on the medical care system.         </p> <p>           There is some evidence that patients with a previous history of basal cell skin carcinoma as well as the broader class of non-melanoma skin cancers are more likely, depending on the number of previous tumors, to develop subsequent skin cancers. However, the studies are limited in scope. This study will explore the previous lesions. This study will utilize one of the local military centers participating in the trial.         </p>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE <b>NOTICE OF INTRAMURAL RESEARCH PROJECT</b>		PROJECT NUMBER Z01 CN 00108 BORB
PERIOD COVERED January 1983 - September 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Design of Pharmacokinetic Studies of Selenium		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and Institute affiliation) Blossom Patterson, M.A.		
COOPERATING UNITS (if any)  Cancer Prevention Studies Branch, DRCCA, Prevention Program		
LAB/BRANCH Biometrics and Operations Research Branch, DRCCA		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 0.30	PROFESSIONAL: 0.25	OTHER: 0.05
CHECK APPROPRIATE BOX(ES) <input type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input checked="" type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>             Selenium is a possible cancer prevention agent, and is being considered for use in intervention trials. Two studies in collaboration with the Cancer Prevention Studies Branch, DRCCA Prevention Program, are planned to provide information on the bioavailability and pharmacokinetics of selenium in its prototype forms—sodium selenite (inorganic form) and selenomethionine (organic form). This information is unavailable for these agents in the dose currently considered optimal, and is necessary to the determination of time and manner of administration. The initial study will be the Selenium Pharmacokinetic Study. Parameters such as percent absorption, maximum concentration, time to maximum concentration, and half-life will be estimated for a single dose and compared in both fasting and nonfasting subjects. A second study, the Selenium Chronic Supplementation Study, will examine and compare the effects of multiple dosing on the absorption, distribution, and excretion of these two forms of selenium and a placebo. The Biometrics and Operations Research Branch, in cooperation with the Cancer Prevention Studies Branch, will function as a data collection center and has primary responsibility for the study design and analysis.           </p>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE <b>NOTICE OF INTRAMURAL RESEARCH PROJECT</b>		PROJECT NUMBER Z01 CN 00109 BORB
PERIOD COVERED January 1983 - September 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Development of Cancer Control Epidemiology and Tracking		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) Douglas L. Weed, M.D., Ph.D., Senior Staff Fellow		
COOPERATING UNITS (if any)		
LAB/BRANCH Biometrics and Operations Research Branch, DRCCA		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: .25	PROFESSIONAL: .20	OTHER: .05
CHECK APPROPRIATE BOX(ES): <input type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input checked="" type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>             The purpose of this effort is to focus on the analytic and design requisites of cancer control. As appropriate, the project will expand upon the current theoretical basis of epidemiology and test the resultant theories in ongoing studies. Epidemiology has focused upon two theoretical representations, cause and chance; yet cancer control goes beyond these. Also, although analytical techniques used in epidemiology have increased, the theoretical development of such techniques has been limited. In this regard, multiple cause-effect relationships have arisen from simple cause-effect relationships. Multiple causal factors can be controlled for in some analyses as confounders, but when control is not possible, these factors (called affect modifiers) are said to interact. Two current models of integration are the additive model and the multiplicative model; each has a corresponding effect measure, the rate difference (also called the attributable risk) and the rate ratio (also called the relative risk) respectively. One investigation currently underway models various interactive states, as they are reflected in the direction of trends in the difference measure and in the ratio measure across the interacting variable of interest. This is a trivial problem when the rates used to calculate the effect measures are constant across the interacting variable; it is non-trivial when these rates take on various functional forms appropriate to epidemiologic investigations, e.g., the Weibull curves of mortality by age.           </p>		





DEPARTMENT OF HEALTH AND HUMAN SERVICES · PUBLIC HEALTH SERVICE NOTICE OF INTRAMURAL RESEARCH PROJECT		PROJECT NUMBER Z01 CN 00110 BORD
PERIOD COVERED October 1, 1983 - September 30, 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Data Management and Design in Clinical Trials for Cancer Prevention and Control		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and Institute affiliation) Brenda K. Edwards, Ph.D. and Blossom Patterson, M.A.		
COOPERATING UNITS (If any) Prevention Program Centers and Community Oncology Program Cancer Control Science Program		
LAB/BRANCH Biometrics and Operations Research Branch, DRCCA		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 1.5	PROFESSIONAL: 1.4	OTHER: 0.1
CHECK APPROPRIATE BOX(ES) <input checked="" type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input checked="" type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.) <p>Large scale, long term controlled trials will be conducted by the Prevention and Cancer Control Science Programs during the next decade. Research in controlled trials methodology is being planned which will investigate three aspects of data management associated with these studies.</p> <p>(1) Field test of micro-computer technology for data capture at local clinical sites using formatted screen data entry via a keyboard or via handwriting. Systems will be evaluated in terms of equipment, development and maintenance costs, portability, ease of use by data managers and clinicians, and quality of data (including timeliness).</p> <p>(2) Development of micro-processor software for onsite data editing and verification, and onsite assistance in conducting the trial according to protocol specifications, to improve data quality and protocol adherence.</p> <p>(3) Utilization of technological developments in computer networking (machine to machine interface within a clinical center and across geographically diverse centers).</p> <p>Research is also planned which addresses design and sample size estimation of prevention trials, e.g., controlled trials with chemoprevention agents or dietary interventions. Feasibility of such trials depends, in part, on the number of individuals required with respect to the number available, which is a function of the incidence of the targeted cancer in a given population. Since traditional designs for single cancer site mortality reduction range from 5,000 to 20,000 to more than 120,000 subjects, alternative designs are under exploration to enable conduct of these critically needed studies undertaken in a scientifically sound manner within feasible operational and fiscal constraints.</p> <p>Such research has direct relevance to chemoprevention controlled trials, nutrition and cancer studies, the Clinical Community Oncology Program, cancer centers, occupational studies and Phase IV demonstration projects.</p>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE NOTICE OF INTRAMURAL RESEARCH PROJECT		PROJECT NUMBER Z01 CN 00111 B0RB
PERIOD COVERED January 1983 - September 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Core Data and Dietary Methodology		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) Gladys Block, Ph.D., Anne Hartman, M.S., William DeWys, M.D.		
COOPERATING UNITS (if any)		
LAB/BRANCH Biometrics and Operations Research Branch, DRCCA		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 1.2	PROFESSIONAL: 1	OTHER: .2
CHECK APPROPRIATE BOX(ES) <input checked="" type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input checked="" type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>Two efforts are underway to enhance the comparability between trials conducted by the Division and ensure the collection of data on important variables in a standardized way. The first, a core questionnaire, is not intended to be exhaustive, but rather to provide a core which each investigation will expand upon. It includes demographic and tracking data, and exposure data including smoking, diet, occupation and psychosocial factors. The development of the areas of investigation and wording of specific questions made use of prior standardization projects and large national surveys. Thus, most questions included in the core data have been subjected to pretesting and will permit comparability of results with representative national data.</p> <p>Second, a dietary assessment questionnaire is being developed for inclusion in the core data to be collected by DRCCA intervention trials, as well as in other diet investigations. The aim is to develop a questionnaire appropriate for large-scale administration and valid for individual, as opposed to group, dietary intake. The method involves a quantitative food frequency questionnaire, in which the list of foods is based on the 200,000 food items reported by the 20,000 individuals examined in NHANES II. The validity of the instrument will be examined in a separate validation study, and a biochemical validation is also planned. In addition, earlier work developed a list of indicator foods for vitamin A assessment, using a similar approach. Further work on this instrument will refine the list of foods and examine its validity and ability to classify individuals with respect to their vitamin A intake.</p> <p>It is expected that the collection of a set of baseline data in an identical manner will improve the interpretation of results from different studies, facilitate the resolution of conflicting data, and thereby enhance the contribution of each study to knowledge about prevention strategies.</p>		



DEPARTMENT OF HEALTH AND HUMAN SERVICES - PUBLIC HEALTH SERVICE NOTICE OF INTRAMURAL RESEARCH PROJECT		PROJECT NUMBER Z01 CN 00112 BORB
PERIOD COVERED June 1983 - September 1983		
TITLE OF PROJECT (80 characters or less. Title must fit on one line between the borders.) Retrospective Dietary Assessment		
PRINCIPAL INVESTIGATOR (List other professional personnel on subsequent pages.) (Name, title, laboratory, and institute affiliation) Gladys Block, Ph.D., Staff Fellow		
COOPERATING UNITS (if any)  Gerontology Research Center, National Institutes of Aging		
LAB/BRANCH Biometrics and Operations Research Branch, DRCCA		
SECTION		
INSTITUTE AND LOCATION National Cancer Institute, NIH, Bethesda, MD		
TOTAL MANYEARS: 1.10	PROFESSIONAL: 1.0	OTHER: 0.10
CHECK APPROPRIATE BOX(ES) <input checked="" type="checkbox"/> (a) Human subjects <input type="checkbox"/> (b) Human tissues <input type="checkbox"/> (c) Neither <input type="checkbox"/> (a1) Minors <input checked="" type="checkbox"/> (a2) Interviews		
SUMMARY OF WORK (Use standard unreduced type. Do not exceed the space provided.)  <p>             This project, now in the design phase, will assess whether or not it is possible to gather accurate information about an individual's past dietary intake. An answer to this question will permit researchers to evaluate retrospective data on the association between diet and cancer, and to plan further studies on this question.           </p> <p>             The study will make use of study subjects for whom dietary data was collected seven to fifteen years ago by means of seven-day diet records. These subjects will be interviewed, and their dietary intake during the past time period assessed by means of a food frequency questionnaire. Results will be evaluated with respect to the ability to classify individuals correctly, and the ability to determine the mean intake of groups.           </p> <p>             In addition to improving the interpretation of observed diet-cancer associations, this technique, if validated, would permit the evaluation of an important potential confounder, past diet, in participants in chemoprevention trials.           </p>		













NIH Library, Building 10  
National Institutes of Health  
Bethesda, Md. 20205



<http://nihlibrary.nih.gov>

---

10 Center Drive  
Bethesda, MD 20892-1150  
301-496-1080

**JRSI  
1985**

NW LIBRARY



3 1496 00312 5914